{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002038","form_type":"8-K","ticker":"SENS","cik":"0001616543","company_name":"Senseonics Holdings, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.200553+00:00","generated_at":"2026-05-25T17:49:46.365871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Senseonics Q4 revenue $8.3M, net loss $15.5M; guides FY25 revenue $34-38M","bullets":["Q4 revenue $8.3M (up from $8.0M YoY); net loss $15.5M ($0.02 loss per share).","Full-year 2024 revenue $22.5M (flat YoY); net loss $78.6M ($0.12 loss per share).","Patient base grew 56% in 2024 to ~6,000 global patients; Eversense 365 FDA approved and launched.","FY2025 guidance: revenue $34-38M, gross margins 25-30%, cash usage $50-60M.","Post-quarter: raised ~$27M via ATM, repaid $20.4M convertible notes; debt reduced to $35M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002038","json":"https://secwatch.observer/filing/0001558370-25-002038.json","markdown":"https://secwatch.observer/filing/0001558370-25-002038.md","text":"https://secwatch.observer/filing/0001558370-25-002038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616543/000155837025002038/0001558370-25-002038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616543/000155837025002038/sens-20250303x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:49:46.365871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}